NRX PHARMACEUTICALS INC

NRX Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company whose drug development pipeline relies on animal testing. The company’s lead candidate, NRX-101, is being developed for suicidal bipolar depression and has progressed through preclinical studies involving animal models to assess efficacy and safety. This reliance on animal testing is standard practice in the pharmaceutical industry but places the company within the scope of commercial animal exploitation.

The specific evidence for NRX Pharmaceuticals’ animal testing practices is not detailed in public disclosures. However, the company’s sector and stage of development indicate that animal models are integral to its research and regulatory submission processes. As a firm with no marketed products, its preclinical work constitutes a core business activity. This record is flagged based on sector-wide practices rather than a publicized incident, reflecting the categorical exclusion of companies whose primary research and development operations depend on animal experimentation.